PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, will showcase its commitment to delivering paradigm-shifting and integrated innovations to personalize the cancer care pathway at the 2024 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 29-Oct. 2, in Washington, D.C..

。。

Radiation therapy, required by roughly half of all cancer patients,1 is a core part of driving toward a world without fear of cancer. Varian is leveraging more than 75 years of innovation to push the boundaries for cancer therapy, from advanced imaging and radiation therapy to comprehensive software and services..

大约一半的癌症患者需要放射治疗，1是推动一个没有癌症恐惧的世界的核心部分。瓦里安正在利用75多年的创新来推动癌症治疗的发展，从先进的成像和放射治疗到全面的软件和服务。。

“As the industry leader in radiotherapy, we have an obligation to simplify the patient pathway and enhance personalized care by taking a holistic approach to care,” said Arthur Kaindl, Head of Varian. “Through our combination with Siemens Healthineers, the industry leader of imaging, we are uniquely poised to accelerate advances in cancer care that improve patient outcomes and experiences, expand access to care, and transform cancer into a manageable chronic disease.”.

瓦里安公司负责人亚瑟·坎德尔（ArthurKaindl）表示：“作为放射治疗行业的领导者，我们有义务通过采取整体护理方法来简化患者路径并增强个性化护理。”。“通过与成像行业领导者西门子医疗集团（Siemens Healthineers）的合作，我们将加速癌症护理的进步，从而改善患者的预后和体验，扩大获得护理的机会，并将癌症转化为可控制的慢性病。”。

Varian will announce ground-breaking new technology at its booth (ASTRO #1627) and virtually on LinkedIn Live, Sunday, Sept. 29, at 1:31 p.m. EDT.

瓦里安将于美国东部时间9月29日星期日下午1:31在其展位（ASTRO#1627）和LinkedIn Live上宣布开创性的新技术。

At ASTRO 2024, Varian will be sharing how its combined, comprehensive portfolio is designed to enhance patient outcomes by making processes easier to implement, more automated, and easier to accomplish.

在ASTRO 2024上，瓦里安将分享其综合全面的投资组合是如何通过使流程更容易实施、更自动化和更容易完成来提高患者预后的。

Unlocking the power of software

释放软件的力量

Varian is using the power of its software to unlock its hardware in new ways, focusing on patient-centric cancer care management and empowering care teams to optimize how they use Varian’s treatment delivery systems and personalize care.

瓦里安正在利用其软件的强大功能以新的方式解锁其硬件，专注于以患者为中心的癌症护理管理，并授权护理团队优化他们如何使用瓦里安的治疗交付系统和个性化护理。

At the heart of this portfolio is Varian’s ARIA CORE oncology management solution, which is designed to support integration across the cancer treatment journey into survivorship. From enabling standardized workflows, enhancing communication and patient engagement, to mobile applications and analytics, Varian’s software solutions aim to streamline care and connect providers and patients to critical information when and where they need it.

该投资组合的核心是瓦里安的ARIA核心肿瘤学管理解决方案，该解决方案旨在支持癌症治疗过程中的生存整合。从实现标准化的工作流程，增强沟通和患者参与度，到移动应用程序和分析，瓦里安的软件解决方案旨在简化护理，并在提供者和患者需要时随时随地将其与关键信息联系起来。

Reflecting its deepening integration with Siemens Healthineers, Varian will also be showcasing Siemens Healthineers DirectSetup Notes,* which enables radiotherapy staff to document patient setup information during simulation directly on the CT scanner's tablet and transfer all recorded information directly to ARIA CORE or other oncology information systems for future reference and analysis..

瓦里安还将展示西门子Healthineers DirectSetup Notes，以反映其与西门子Healthineers的深入集成，*它使放射治疗人员能够在模拟过程中直接在CT扫描仪的平板电脑上记录患者设置信息，并将所有记录的信息直接传输到ARIA CORE或其他肿瘤学信息系统，以备将来参考和分析。。

Connecting the power of imaging

连接成像功能

Varian’s portfolio demonstrates its commitment to sustained innovation, introducing new capabilities to optimize treatment procedures and personalize care by connecting powerful imaging technology.

瓦里安的产品组合表明了其对持续创新的承诺，通过连接强大的成像技术，引入了优化治疗程序和个性化护理的新功能。

HyperSight imaging, an optional feature for various Varian linacs, brings fast, highly accurate imaging into the treatment room, enabling the acquisition of cone-beam CT images in as little as six seconds, with the Hounsfield Unit (HU) accuracy required for calculating dose distributions directly on the images, depending on system configuration.

HyperSight成像是各种Varian直线加速器的可选功能，可将快速，高精度的成像带入治疗室，使锥束CT图像的采集只需6秒钟，根据系统配置，Hounsfield单位（HU）的精度可直接计算图像上的剂量分布。

The HyperSight image reconstruction algorithms, combined with its expanded field of view (FOV), offer improved visualization of larger areas of interest, often encompassing the entire target volume and surrounding organs at risk (OARs). Varian’s Ethos adaptive radiotherapy system, updated with several new software features in 2024, provides care teams with the flexibility to choose between online or offline adaptive, as well as image-guided radiation therapy (IGRT) treatment, for precise delivery of intensity-modulated radiation therapy (IMRT) and RapidArc volumetric modulated arc therapy (VMAT)..

HyperSight图像重建算法结合其扩展的视野（FOV），可以改进更大感兴趣区域的可视化，通常包括整个目标体积和周围的危险器官（OAR）。瓦里安的Ethos自适应放射治疗系统于2024年更新了几个新的软件功能，为护理团队提供了在在线或离线自适应以及图像引导放射治疗（IGRT）治疗之间进行选择的灵活性，以精确提供调强放射治疗（IMRT）和RapidArc容积调制电弧治疗（VMAT）。。

Enabling care teams to streamline, personalize care

使护理团队能够简化、个性化护理

Varian’s innovative product ecosystem highlights its unique, combined capabilities and commitment to embrace innovation and enhance outcomes for today’s patients, and the 35 million people who will develop cancer annually by 2050.

瓦里安的创新产品生态系统突出了其独特的综合能力和承诺，以拥抱创新，提高当今患者以及到2050年每年将有3500万人患癌症的结果。

Reflecting Varian’s commitment to helping care teams harness the full power of its technology is its Advanced Oncology Solutions (AOS), a team of world-class experts providing a robust combination of customized solutions and services. These solutions help clinical teams realize their unique goals for optimizing, upgrading, or standardizing operations while implementing global best practices in cancer care..

瓦里安的先进肿瘤学解决方案（AOS）体现了瓦里安帮助护理团队充分利用其技术力量的承诺，该团队由世界一流的专家组成，提供定制解决方案和服务的强大组合。这些解决方案帮助临床团队实现优化、升级或标准化操作的独特目标，同时实施全球癌症护理最佳实践。。

“We’re excited to share how our combined portfolio of innovative and integrated products and services are designed to work together to truly advance the possibilities of cancer care,” Kaindl said. “We are committed to driving sustainable innovations that introduce new and enhanced tools to help move us forward to a world without fear of cancer.”.

Kaindl说：“我们很高兴分享我们创新和集成产品与服务的组合是如何设计的，以共同努力，真正提高癌症护理的可能性。”。“我们致力于推动可持续创新，引入新的和增强的工具，帮助我们迈向一个没有癌症恐惧的世界。”。

*DirectSetup Notes is enabled with syngo CT VB10 on Siemens Healthineers CT simulators SOMATOM go.Sim and SOMATOM go.Open Pro.

*DirectSetup Notes在西门子Healthineers CT模拟器SOMATOM go上使用syngo CT VB10启用。Sim和SOMATOM走了。打开Pro。

© 2024 Varian Medical Systems, Inc. All rights reserved. VARIAN, ARIA CORE, ETHOS, HYPERSIGHT, and RAPIDARC are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off. DIRECTSETUP NOTES, SYNGO, SOMATOM GO.SIM and SOMATOM GO.OPEN PRO are trademarks of Siemens Healthcare GmbH registered U.S.

©2024 Varian Medical Systems，Inc.保留所有权利。Tm。关闭。DIRECTSETUP NOTES，SYNGO，SOMATOM GO。SIM和SOMATOM走了。OPEN PRO是Siemens Healthcare GmbH在美国注册的商标。

Pat. & Tm. Off..

专利和Tm关闭。。

About Varian

关于瓦里安

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship.

在西门子Healthineers公司Varian，我们设想一个没有癌症恐惧的世界。75多年来，瓦里安开发、制造并提供了创新技术和解决方案，帮助全球护理提供者每年治疗数百万患者。今天，作为西门子Healthineers公司，我们支持癌症护理旅程的每一步，从筛查到生存。

From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight.

从先进的成像和放射治疗到全面的软件和服务，再到介入放射学，我们正在利用我们的观点的力量，同时也在进行临床研究，以创建更高效，更个性化的护理途径。因为，对于世界各地的癌症患者来说，他们的斗争就是我们的斗争。

For more information, visit http://www.varian.com..

For more information, visit http://www.varian.com..

______________________________

______________________________

1 M Abdel-Wahab, et al. JCO Global Oncol. 2021(7):827-842.

Abdel Wahab等人，JCO全球肿瘤。2021（7）：827-842。